C12N 2730/10134
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2730/10134 (Use of virus or viral component as vaccine) appears on 440 US grants and 745 published applications in this corpus.
Search patents in C12N- Granted patents
- 440
- Published applications
- 745
- Assignees
- 397
- Inventors
- 1,405
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 2 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 1 | 0 |
| 1987 | 4 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 4 | 0 |
| 1998 | 10 | 0 |
| 1999 | 4 | 0 |
| 2000 | 5 | 0 |
| 2001 | 4 | 4 |
| 2002 | 12 | 21 |
| 2003 | 7 | 33 |
| 2004 | 8 | 30 |
| 2005 | 9 | 36 |
| 2006 | 12 | 26 |
| 2007 | 10 | 16 |
| 2008 | 14 | 29 |
| 2009 | 13 | 29 |
| 2010 | 10 | 35 |
| 2011 | 8 | 29 |
| 2012 | 15 | 24 |
| 2013 | 11 | 27 |
| 2014 | 28 | 38 |
| 2015 | 12 | 33 |
| 2016 | 32 | 41 |
| 2017 | 18 | 46 |
| 2018 | 28 | 23 |
| 2019 | 24 | 33 |
| 2020 | 22 | 28 |
| 2021 | 17 | 29 |
| 2022 | 22 | 48 |
| 2023 | 18 | 23 |
| 2024 | 16 | 27 |
| 2025 | 17 | 22 |
| 2026 | 5 | 15 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Treatment of diseases related to hepatitis B virus18 Aug 2026US 12,709,634 B2Erasmus University Medical Center Rotterdam
- Adenoviral vectors encoding hepatitis B viral antigens fused to herpes virus glycoprotein D and methods of using the same21 Apr 2026US 12,605,444 B2The Wistar Institute
- Hepatitis B virus-specific T cell responses14 Apr 2026US 12,599,658 B2Oregon Health & Science University
- Triterpene saponin analogues10 Mar 2026US 12,569,554 B2Adjuvance Technologies, Inc.
- HBV vaccine13 Jan 2026US 12,521,431 B2Oxford University Innovation Limited
- Tumor neoantigen vaccine system specifically marking heterologous protein, and use thereof8 Oct 2026US 2026/0306620 A1China Pharmaceutical University
- Oligonucleotides for use in modulating immune responses against hepatitis b viral infection3 Sep 2026US 2026/0256907 A1Ausperbio Therapeutics Inc.
- A Fusion Protein and a Particulate Antigen Containing the Same27 Aug 2026US 2026/0250328 A1Xiamen Innovax Biotech Co., Ltd.
- Hepatitis B Compositions23 Jul 2026US 2026/0207736 A1Glaxosmithkline Biologicals SA
- Dna vaccine composition comprising hepatitis virus b-derived mutant molecule and pathogen- or tumor-associated antigen molecule and use thereof23 Jul 2026US 2026/0209278 A1Seoul National University R&Db Foundation
Most cited
By later US patents
- Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant395US 6,406,705 B1Coley Pharmaceutical GmbH · 2002
- Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix365US 6,309,669 B1The United States of America as represented by the Secretary of the Army · 2001
- Vectors and methods for immunization or therapeutic protocols285US 6,339,068 B12002
- Method for immunizing animals with synthetically modified vaccinia virus240US 4,722,848 AHealth Research, Inc. · 1988
- Compositions and methods for delivery of genetic material184US 5,739,118 AApollon Inc. · 1998